Physician profile
Brian Alan Baxter
NPI 1649220450
$1,292.61
in general payments reported to CMS, 2019-2025
23 companies · $209 in 2025
The $209 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.33 · 2020: $119 · 2021: $287 · 2022: $190 · 2023: $122 · 2024: $293 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $623.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $474.58 | 2021-2025 | Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals Lp | $121.23 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $91.91 | 2020-2024 | Wegovy |
| Lilly USA, LLC | $76.47 | 2019-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $69.25 | 2025 | The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $65.76 | 2020-2024 | Arexvy, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $44.40 | 2022 | |
| Amgen INC. | $33.68 | 2019-2025 | Repatha |
| Otsuka America Pharmaceutical, INC. | $31.76 | 2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $31.00 | 2021-2022 | |
| Medtronic, INC. | $29.09 | 2023 | Turbohawk |
| Viiv Healthcare Company | $28.45 | 2025 | Apretude |
| Pfizer INC. | $27.58 | 2021 | |
| Dexcom, INC. | $25.30 | 2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $24.04 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $21.07 | 2021 | |
| Abbott Laboratories | $17.96 | 2025 | Freestyle Libre 3 |
| Eisai INC. | $14.61 | 2021 | |
| Bard Peripheral Vascular, INC. | $14.36 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $13.69 | 2020 | |
| Amarin Pharma, INC. | $13.46 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.63 | 2020 | |
| Allergan, INC. | $11.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Baxter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.